PCDHB3: A Non-Coding RNA Molecule with Potential as A Drug Target and Biomarker

Target Name: PCDHB3

NCBI ID: G56132

PCDHB3

PCDHB3: A Non-Coding RNA Molecule with Potential as A Drug Target and Biomarker

PCDHB3 (PCDH-BETA3) is a gene that encodes a protein known as PCDHB3. PCDHB3 is a non-coding RNA molecule that has been shown to play a role in the development and progression of various diseases, including cancer.

One of the key functions of PCDHB3 is its ability to act as a drug target. Many studies have shown that PCDHB3 can be targeted by small molecules, such as inhibitors, to induce apoptosis (programmed cell death) in cancer cells. These inhibitors can disrupt the activity of PCDHB3 and cause cancer cells to stop dividing and die.

Another function of PCDHB3 is its role as a biomarker. The expression of PCDHB3 has been shown to be associated with the development and progression of various diseases, including cancer. By measuring the levels of PCDHB3 in tissue samples or blood samples, researchers can monitor the effectiveness of treatments and track the progress of diseases.

In addition to its potential as a drug target and biomarker, PCDHB3 is also a promising candidate for future research into the regulation of cell growth and differentiation. Many scientists are currently investigating the mechanisms by which PCDHB3 regulates cell growth and are working to develop new treatments that target this protein.

Overall, PCDHB3 is a complex gene that has important functions in the regulation of cell growth and differentiation. Its potential as a drug target and biomarker make it an attractive target for future research into the development of new treatments for a variety of diseases.

Protein Name: Protocadherin Beta 3

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHB3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHB3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets